INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Integra LifeSciences Holdings Corporation

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
29.24 ^USD	+3.18%		+0.90%	-32.86%

04-04	North American Morning Briefing : Focus Turns to -2-	DJ
04-03	Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target	MT

Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on December 10, 2020.

April 27, 2022 at 06:16 am

From January 1, 2022 to March 31, 2022, the company has repurchased 1,940,000 shares, representing 2.29% for $125 million. With this, the company has completed the repurchase of 1,940,000 shares, representing 2.29% for $125 million under the buyback announced on December 10, 2020.

Latest news about Integra LifeSciences Holdings Corporation

North American Morning Briefing : Focus Turns to -2-	04-04	DJ
Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target	04-03	MT
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target is $38	04-03	MT
Integra LifeSciences Completes Acquisition of Acclarent	04-01	MT
Integra LifeSciences Holdings Corporation acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.	03-31	CI
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases	03-11	CI
Integra Lifesciences Holdings Insider Sold Shares Worth $305,492, According to a Recent SEC Filing	03-08	MT
Truist Securities Cuts Price Target on Integra LifeSciences Holdings to $41 From $46, Maintains Hold Rating	03-01	MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023.	02-28	CI
Integra LifeSciences Shares Drop Following Q4 Results	02-28	MT
Integra LifeSciences Seeks Acquisitions	02-28	CI
Transcript : Integra LifeSciences Holdings Corporation, Q4 2023 Earnings Call, Feb 28, 2024	02-28
Integra LifeSciences' Q4 Adjusted Earnings, Revenue Decline	02-28	MT
Integra LifeSciences Holdings Corporation Announces the Retirement of Jan De Witte as Chief Executive Officer	02-28	CI
Integra LifeSciences Holdings Corporation Announces Board Changes	02-28	CI
Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024	02-28	CI
Integra LifeSciences Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q4 Revenue $397M, vs. Street Est of $399.2M	02-28	MT
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Reports Q4 EPS $0.89, vs. Street Est of $0.90	02-28	MT
Integra LifeSciences Holdings Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Integra LifeSciences Holdings Corporation Appoints Jeffrey Alan Graves on the Compensation Committee of the Board	02-27	CI
Transcript : Integra LifeSciences Holdings Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	01-10
Truist Securities Adjusts Price Target on Integra LifeSciences to $46 From $44, Maintains Hold Rating	12-22	MT
Truist Adjusts Integra LifeSciences Holdings' Price Target to $44 From $39, Keeps Hold Rating	12-14	MT
Integra LifeSciences Agrees to Buy Acclarent for $275 million at Deal Closing	12-13	MT

Chart Integra LifeSciences Holdings Corporation

Duration

Period

Chart Integra LifeSciences Holdings Corporation

More charts

Company Profile

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Integra LifeSciences Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

29.24 USD

Average target price

44.8 USD

Spread / Average Target

+53.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION	-32.86%	2.3B
ABBOTT LABORATORIES	-2.54%	186B
MEDTRONIC PLC	-1.85%	107B
BECTON, DICKINSON AND COMPANY	-4.26%	67.44B
DEXCOM, INC.	+1.39%	50.03B
CENCORA, INC.	+16.82%	47.81B
HOYA CORPORATION	+4.79%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	25.82B
TERUMO CORPORATION	+16.55%	24.74B

Other Medical Equipment, Supplies & Distribution